Voluntary announcement
Filed with HKEX · Stock code 9996 · · 2 pages · English
Summary by 6ix AI
Peijia Medical Ltd. has made a voluntary announcement regarding the approval from the National Medical Products Administration for its SeQuent Please CIS paclitaxel drug-coated intracranial balloon dilatation catheter. This product is designed to treat intracranial vascular diseases by delivering paclitaxel to the affected area during mechanical dilatation. The company warns that it may not successfully market this product and advises shareholders and potential investors to exercise caution.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Peijia Medical
- Notification Letter and Reply Form to Non-registered Shareholders - Reminder Letter regarding the Arrangement of Electronic Dissemination of Corporate Communications
- Interim Report 2026
- Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth
- Peijia Medical Announces 2025 Annual Results
- DCwire® Micro Guidewire Receives FDA 510(k) Clearance, Marking a Key Milestone in Peijia Medical's Global Expansion
Later from Peijia Medical
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2026
Follow Peijia Medical into a list and get an email when it puts out news.
Follow Peijia Medical